Emergent BioSolutions, Inc. (EBS)
5.05
-0.10
(-1.94%)
USD |
NYSE |
Nov 20, 16:00
5.07
+0.02
(+0.40%)
Pre-Market: 20:00
Emergent BioSolutions Debt to Equity Ratio : 1.640 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.640 |
| June 30, 2026 | 1.723 |
| March 31, 2026 | 1.214 |
| December 31, 2025 | 1.117 |
| September 30, 2025 | 1.152 |
| June 30, 2025 | 1.261 |
| March 31, 2025 | 1.217 |
| December 31, 2024 | 1.400 |
| September 30, 2024 | 1.330 |
| June 30, 2024 | 2.270 |
| March 31, 2024 | 1.389 |
| December 31, 2023 | 1.352 |
| September 30, 2023 | 1.262 |
| June 30, 2023 | 0.9619 |
| March 31, 2023 | 1.176 |
| December 31, 2022 | 1.028 |
| September 30, 2022 | 0.7416 |
| June 30, 2022 | 0.5591 |
| March 31, 2022 | 0.5469 |
| December 31, 2021 | 0.5405 |
| September 30, 2021 | 0.5773 |
| June 30, 2021 | 0.5737 |
| March 31, 2021 | 0.5849 |
| December 31, 2020 | 0.6275 |
| September 30, 2020 | 0.7227 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.6784 |
| March 31, 2020 | 0.7593 |
| December 31, 2019 | 0.7689 |
| September 30, 2019 | 0.8148 |
| June 30, 2019 | 0.8666 |
| March 31, 2019 | 0.7657 |
| December 31, 2018 | 0.786 |
| September 30, 2018 | 0.014 |
| June 30, 2018 | 0.0144 |
| March 31, 2018 | 0.0153 |
| December 31, 2017 | 0.0147 |
| September 30, 2017 | 0.3752 |
| June 30, 2017 | 0.4007 |
| March 31, 2017 | 0.4069 |
| December 31, 2016 | 0.4497 |
| September 30, 2016 | 0.489 |
| June 30, 2016 | 0.3678 |
| March 31, 2016 | 0.3706 |
| December 31, 2015 | 0.3741 |
| September 30, 2015 | 0.418 |
| June 30, 2015 | 0.45 |
| March 31, 2015 | 0.4666 |
| December 31, 2014 | 0.4537 |
| September 30, 2014 | 0.4891 |
| June 30, 2014 | 0.5146 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Vertex Pharmaceuticals, Inc. | 0.3099 |
| Arcturus Therapeutics Holdings, Inc. | 0.1296 |
| Travere Therapeutics, Inc. | 27.28 |
| Syndax Pharmaceuticals, Inc. | -34.31 |
| Novavax, Inc. | -1.362 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 995.20M |
| Total Liabilities (Quarterly) | 682.00M |
| Shareholders Equity (Quarterly) | 313.20M |
| Current Ratio | 4.575 |
| Net Debt Paydown Yield | 9.59% |